Avenacy Announces Launch of Eptifibatide for Injection in the U.S. Market
29 April 2024 - 1:00PM
Business Wire
Avenacy, a specialty pharmaceutical company focused on supplying
critical injectable medications, today announced it has launched
Eptifibatide for Injection in the United States as a therapeutic
equivalent generic for Integrilin® for Injection (Eptifibatide)
approved by the U.S. Food and Drug Administration. Eptifibatide for
Injection is indicated for use in acute coronary syndrome (ACS) and
percutaneous coronary intervention (PCI).
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240429526438/en/
(Photo: Business Wire)
Avenacy’s Eptifibatide for Injection is available as a 75 mg/100
mL single-dose vial. In line with Avenacy’s mission to champion
patient safety and streamline patient care, Eptifibatide for
Injection will feature the Company’s highly differentiated
packaging and labeling to support accurate medication
selection.
Avenacy will begin shipping Eptifibatide for Injection to
wholesale partners this week. The Company is supported by a global
network of development and FDA-approved cGMP-certified contract
manufacturing partners.
Eptifibatide for Injection had U.S. sales of approximately $8.3
million for the twelve months ending in June 2023.1
Approved Indications:
Acute Coronary Syndrome (ACS) Eptifibatide injection is
indicated to decrease the rate of a combined endpoint of death or
new myocardial infarction in patients with ACS (unstable
angina/non-ST-elevation myocardial infarction), including patients
who are to be managed medically and those undergoing percutaneous
coronary intervention.
Percutaneous Coronary Intervention (PCI) Eptifibatide
injection is indicated to decrease the rate of a combined endpoint
of death, new MI, or need for urgent intervention in patients
undergoing PCI, including those undergoing intracoronary
stenting.
Please see link for Full Prescribing Information.
Integrilin® is a registered trademark of Merck.
1Source: IQVIA
About Avenacy
Avenacy is a U.S.-based specialty pharmaceutical company focused
on supplying critical injectable medications used to treat patients
in various medically supervised settings, from acute care hospitals
to outpatient clinics and physician offices. Through a rigorous and
optimized selection process, the Company is building out a pipeline
of high-quality FDA approved injectable products in order to ensure
a resilient portfolio that can meet the needs of today’s dynamic
drug supply chain. With an experienced team, commitment to quality
and reliability, and product offerings intended to facilitate safe
and efficient patient care, Avenacy strives to be a trusted partner
for essential medications.
Avenacy was launched in 2023 and is headquartered in Schaumburg,
IL. For more information, please visit http://www.avenacy.com/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240429526438/en/
FTI Consulting Avenacy@fticonsulting.com